Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain

PharmacoEconomics

Volumn 32, Issue 9, 2014, Pages 919-936

  Gómez Outes, Antonio ^a   Avendaño Solá, Cristina ^b   Terleira Fernández, Ana Isabel ^c,d   Vargas Castrillón, Emilio ^c,d  

^a Parque Empresarial Las Mercedes   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; ENOXAPARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN;

ADVERSE EFFECTS; COST BENEFIT ANALYSIS; DECISION TREE; ECONOMICS; HIP ARTHROPLASTY; KNEE ARTHROPLASTY; PHARMACOECONOMICS; SPAIN; STATISTICAL MODEL; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; COST-BENEFIT ANALYSIS; DABIGATRAN; DECISION TREES; ECONOMICS, PHARMACEUTICAL; ENOXAPARIN; MODELS, ECONOMIC; PYRAZOLES; PYRIDONES; RIVAROXABAN; SPAIN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84939895394     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0175-5     Document Type: Article

References (51)

1. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28:370–2.
2. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756–64.
3. Guijarro-Merino R, Montes-Santiago J, San Román-Terán CM. Epidemiología hospitalaria de la enfermedad tromboembólica venosa en España. Med Clin (Barc). 2008;131(Suppl. 2):2–9.
4. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S–325S.
5. National Institute for Health and Care Excellence (NICE). Guideline on venous thromboembolism. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Clinical guideline CG92, January 2010. http://guidance.nice.org.uk/CG92. Accessed 13 Jul 2013.
6. Arcelus JL, Monreal M, Caprini JA, et al. Clinical presentation and time-course of postoperative venous thromboembolism: results from the RIETE Registry. Thromb Haemost. 2008;99:546–51.
7. Summary of product characteristics of ‘Clexane 40 mg (4.000 UI) solución inyectable en jeringa precargada’. Centro de información online de medicamentos de la AEMPS (CIMA). http://www.aemps.gob.es/cima/especialidad.do?metodo=verFichaWordPdf&codigo=58503&formato=pdf&formulario=FICHAS&file=ficha.pdf. Accessed 13 Jul 2013.
8. Craik JD, Cobb AG. Heparin-induced thrombocytopenia following hip and knee arthroplasty. Br J Haematol. 2013;161:255–61.
9. Gómez-Outes A, Lecumberri R, Pozo C, et al. New anticoagulants: focus on venous thromboembolism. Curr Vasc Pharmacol. 2009;7:309–29.
10. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010;104:49–60.
11. Summary of product characteristics of Pradaxa 110 mg hard capsules. European Medicines Agency (EMA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed 13 Jul 2013.
12. Summary of product characteristics of Xarelto 10 mg film coated tablets. European Medicines Agency (EMA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed 13 Jul 2013.
13. Summary of product characteristics of Eliquis 2.5 mg film coated tablets. European Medicines Agency (EMA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed 13 Jul 2013.
14. Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A, et al. Rivaroxaban versus enoxaparin after total knee arthroplasty. Lancet. 2009;374:682.
15. Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A, et al. Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient? J Thromb Haemost. 2009;7:2149–50.
16. Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344:e3675.
17. Sullivan SD, Kahn SR, Davidson BL, et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics. 2003;21:477–96.
18. Davidson BL, Sullivan SD, Kahn SR, et al. The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003;124(6 Suppl):393S–6S.
19. Monreal M, González-Rojas N, Vieta A, et al. Análisis económico de dabigatrán etexilato en prevención primaria del tromboembolismo venoso tras artroplastia total de cadera o rodilla. Pharmacoeconomics Spanish Research Articles. 2009;6:126–45.
20. Gómez-Cerezo JF, Gómez-Arrayás I, Suárez-Fernández C, et al. Análisis coste-efectividad de apixaban frente a dabigatrán en la prevención de la tromboembolia venosa en pacientes intervenidos de artroplastia total de rodilla o de cadera. Rev Esp Cir Ortop Traumatol. 2012;56:459–70.
21. Brosa M, Monreal M, Piñol C. Análisis coste-efectividad de rivaroxabán en la prevención de la enfermedad tromboembólica venosa en España. Pharmacoeconomics Spanish Research Articles. 2012;9:33–44.
22. Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal, 2011. http://www.msssi.gob.es/estadEstudios/estadisticas/cmbd.htm. Accessed 3 Aug 2013.
23. Wee HL, Machin D, Loke WC, et al. Assessing differences in utility scores: a comparison of four widely used preference-based instruments. Value Health. 2007;10:256–65.
24. Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009;31:194–212.
25. Krauel K, Hackbarth C, Fürll B, et al. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood. 2012;119:1248–55.
26. Baroletti S, Piovella C, Fanikos J, et al. Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost. 2008;100:1130–5.
27. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007;89:799–807.
28. Davies LM, Richardson GA, Cohen AT. Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. Value Health. 2000;3:397–406.
29. Santamaría A, Juárez S, Reche A, et al. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. Int J Clin Pract. 2006;60:518–25.
30. Rasanen P, Paavolainen P, Sintonen H, et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthop. 2007;78:108–15.
31. Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement: a cost-utility analysis. Arch Orthop Trauma Surg. 2004;124:507–17.
32. Hogg K, Kimpton M, Carrier M, et al. Estimating quality of life in acute venous thrombosis. JAMA Intern Med. 2013;173:1067–72.
33. Instituto Nacional de Estadística Tasas de inflación. Actualización de rentas con el IPC general. http://www.ine.es/calcula/. Accessed 3 Aug 2013.
34. BOT PLUS 2.0: Base de datos del conocimiento sanitario [CD-ROM]. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos; 2013.
35. Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. Boletín Oficial del Estado, lunes 24 de mayo de 2010. http://www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010-8228.pdf. Accessed 3 Aug 2013.
36. Lecumberri R, Panizo E, Gomez-Guiu A, et al. Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients. J Thromb Haemost. 2011;9:1108–15.
37. Orden SAN/12/2011, de 20 de abril, por la que se fijan las cuantías de los precios públicos de los Servicios Sanitarios prestados por el Servicio Cántabro de Salud. Boletín Oficial de Cantabria, jueves 5 de mayo de 2011. http://boc.cantabria.es/boces/verAnuncioAction.do?idAnuBlob=207241. Accessed 13 Jul 2013.
38. Resolución de 16 de junio de 2009, del Instituto Nacional de Gestión Sanitaria, sobre revisión de precios a aplicar por los centros sanitarios de las Ciudades Autónomas de Ceuta y Melilla por las asistencias prestadas en los supuestos cuyo importe ha de reclamarse a los terceros obligados al pago o a los usuarios sin derecho a la asistencia sanitaria de la Seguridad Social, así como por los servicios prestados por el Centro Nacional de Dosimetría y por la reproducción de documentos de la biblioteca de la entidad gestora. Boletín Oficial del Estado, lunes 22 de junio de 2009. http://www.boe.es/boe/dias/2009/06/22/pdfs/BOE-A-2009-10262.pdf. Accessed 13 Jul 2013.
39. ORDEN 629/2009, de 31 de agosto, de la Consejería de Sanidad, por la que se fijan los precios públicos por la prestación de los servicios y actividades de naturaleza sanitaria de la red de centros de la Comunidad de Madrid. Boletín Oficial de la Comunidad de Madrid, jueves 10 de septiembre de 2009. http://www.bocm.es/boletin/CM_Orden_BOCM/2009/09/10/2009-09-10_09092009_0002.pdf. Accessed 13 Jul 2013.
40. RESOLUCIÓN 882/2010, de 3 de mayo, del Director Gerente del Servicio Navarro de Salud-Osasunbidea, por la que se actualizan las tarifas por prestación de servicios en los centros y establecimientos asistenciales del Servicio Navarro de Salud-Osasunbidea. Boletín Oficial de Navarra, viernes 11 de junio de 2010. http://www.navarra.es/home_es/Actualidad/BON/Boletines/2010/71/Anuncio-10/. Accessed 13 Jul 2013.
41. Wilke T, Tesch S, Scholz A, et al. The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis. J Thromb Haemost. 2009;7:766–73.
42. Kudrna J. New oral anticoagulants after total knee arthroplasty: clinical considerations for orthopaedic surgeons. Curr Orthop Pract. 2013;24:424–32.
43. Haut ER, Lau BD, Streiff MB. New oral anticoagulants for preventing venous thromboembolism. BMJ. 2012;344:e3820.
44. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158:1525–31.
45. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis: prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82:423–8.
46. Masotti L, Di Napoli M, Godoy DA, et al. The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. Int J Stroke. 2011;6:228–40.
47. Sicras-Mainar A, De Salas-Cansado M, Ruiz-Antorán MB, et al. Utilización de recursos sanitarios y costes asociados al diagnóstico y tratamiento de cada episodio de trombosis venosa profunda y sangrado en pacientes intervenidos de cirugía ortopédica de cadera o rodilla. Rev Esp Cir Ortop Traumatol. 2012;56:341–53.
48. Turpie AGG, Schmidt A, Lassen MR, et al. Rivaroxaban for thromboprophylaxis after total hip or knee replacement surgery: comparison of outcomes of the XAMOS and RECORD studies [abstract no. 500]. Blood (ASH annual meeting abstracts). 2012;120:Abstract 1160.
49. Dahl OE, Quinlan DJ, Bergqvist D, et al. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost. 2010;8:1966–75.
50. National Institute for Health and Care Excellence (NICE). Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance 245, London; 2012. http://www.nice.org.uk/nicemedia/live/13648/57895/57895.pdf. Accessed 10 Jan 2014.
51. Honorato J, Gómez-Outes A, Navarro-Quilis A, et al. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics. 2004;22:885–94.